|
The Romanian division of Actavis is the Group's center of excellence in the development, production and marketing of oncology generics, and a leader in strenghtening the hospital business.
Presently, Actavis has about 320 employees in Romania, out of which around 75 represent the Retail Unit sales force and another 15 are in charge with the Hospitals sales.
The Company holds 130 marketing authorisations for oncology products in 15 European countries, Japan and the US. Over 350 dossiers for MAs are under approval. The production facility in Bucharest is approved by the MHRA for sales in the European Union, while in early 2007, a successful FDA inspection laid grounds for the Company's products to be registered on the US market. Consequently, in March 2008, the oncology injectable Irinotecan Hydrochloride was launched in the US, the world's most competitive market.
Contact information:
Actavis Romania
11 Ion Mihalache Blvd.
Bucharest, 011171
Romania
Tel.: +4021 318 17 67
Fax: +4021 312 44 99
Subsidiary
179-185 Odaii Street
Bucharest, 013604
Romania
Tel.: +4021 351 45 67
Fax: +4021 351 45 65
Country Manager: Laurentiu Scheusan
Email: inforo@actavis.com
http://actavis.com.ro |